Skip to main content

Table 1 Baseline characteristics and measurements of the total group, stratified by randomisation group

From: Does paracetamol improve quality of life, discomfort, pain and neuropsychiatric symptoms in persons with advanced dementia living in long-term care facilities? A randomised double-blind placebo-controlled crossover (Q-PID) trial

  Paracetamol-placebo, N = 47 Placebo-paracetamol, N = 48
Mean age (SD) in years 83.9 (7.5) 83.9 (7.7)
Female (%) 27 (57.4) 28 (58.3)
GDS score 7 (%) 10 (21.3) 10 (20.8)
FCI, 0–18 (SD) 2.9 (1.9) 2.5 (2.1)
QUALIDEM-6D
Total score 0–100 (SD) 58.1 (13.1) 57.0 (13.8)
A—Care relationship 0–100 (SD) 58.0 (22.3) 56.9 (23.0)
B—Positive affect 0–100 (SD) 69.6 (18.6) 68.4 (19.7)
C—Negative affect 0–100 (SD) 63.8 (28.0) 64.2 (25.0)
D—Restless tense behaviour 0–100 (SD) 37.9 (25.5) 39.8 (28.6)
F—Social relationships 0–100 (SD) 64.0 (21.2) 58.8 (20.9)
G—Social isolation 0–100 (SD) 55.1 (20.8) 53.7 (23.7)
DS-DAT, 0–27 (SD) 8.4 (4.9) 8.3 (6.0)
Pain (MOBID-2 ≥ 3) (%) 15 (33.3)* 15 (31.3)
MOBID-2 overall pain intensity, 0–10 (SD) 2.0 (2.4) 2.3 (3.0)
NPI-NH
Total score, 0–144 (SD) 32.6 (21.0) 33.5 (18.9)
Psychosis 0–24 (SD) 3.7 (5.8) 3.7 (4.6)
Agitation 0–48 (SD) 10.7 (8.6) 11.9 (9.7)
Affective symptoms 0–24 (SD) 5.9 (6.2) 4.8 (5.7)
No psychotropic use (%) 29 (61.7)** 19 (39.6)**
  1. SD standard deviation, GDS Global Deterioration Scale, FCI Functional Comorbidity Index, QUALIDEM-6D dementia-specific QoL measurement instrument, 6 domain version, DS-DAT Discomfort Scale-Dementia of Alzheimer Type, MOBID-2 Mobilization-Observation-Behaviour-Intensity-Dementia-2 pain scale, NPI-NH Neuropsychiatric Inventory—Nursing Home version
  2. *Missing, 2
  3. **p value 0.031 (Pearson chi-square)
  4. Psychotropics: antipsychotics, antidepressants, anxiolytics, hypnotics and anti-dementia drugs